Sarepta Therapeutics (SRPT - Get Report) disappoints me.
By publicizing its outreach to the U.S. government about an experimental ebola treatment, Sarepta comes off looking like just another opportunistic, self-promoting drug developer. Sarepta isn't wrong to remind the U.S. government about the drug in its freezer which might be effective against the ebola virus, but why talk to the media about it?
If Sarepta's ebola contract with the government is revived, issue a press release on the material news. Until then, the company should emulate the respectable low-key approach taken by Tekmira Pharmaceuticals (TKMR) and not the crass, stock-pumping antics of Hemispherx Biopharma (HEB - Get Report) or NewLink Genetics (NLNK - Get Report).
Ebola is big news today, but Sarepta has one job right now: Finishing the eteplirsen regulatory package and delivering it to the FDA for review before the end of the year. Nothing else is more important to Sarepta, shareholders or Duchenne muscular dystrophy (DMD) patients and their families. Talking up ebola sounds like a distraction from Sarepta's priority. It sounds like the company is losing focus.
When a DMD parent frustrated by Sarepta inability to make enough eteplirsen for a compassionate use program reads a sentence like the one below, it's a slap in the face:
Sarepta Therapeutics says it has enough doses of its injectible drug - AVI-7537 - to treat about two dozen patients within a week and could ramp up a supply for another 100 patients within a few months.
10/14/15 - 11:47 AM EDT
05/19/15 - 04:42 PM EDT
05/19/15 - 12:48 PM EDT
05/18/15 - 08:06 AM EDT
05/05/15 - 02:43 PM EDT
04/29/16 - 15:55 PM EDT
04/29/16 - 15:33 PM EDT
04/29/16 - 11:02 AM EDT
04/29/16 - 10:51 AM EDT
04/25/16 - 01:00 AM EDT
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.
Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.